Article
Targeted Ablation of Canonical Disulfide Bonds Mitigates TCR Mismatching in Engineered T Cells
2025-06-01
Abstract excerpt
T cell receptor-engineered T (TCR-T) cell therapy holds distinct advantages over chimeric antigen receptor (CAR)-T cell therapy in treating solid tumors by exploiting intracellular targets through MHC-mediated antigen presentation. Despite this potential, only one TCR-T therapy has received FDA approval to date. A key challenge lies in chain mispairing between exogenous therapeutic TCR chains and endogenous TCR ch...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 9fbe3f50-f8ec-517c-8f9d-a358b59fd1d4
- DOI
- 10.1101/2025.05.28.656745
